REGULATORY
    May Listing OK’ed for Darzquro, Pemazyre, Vitrakvi, Kesimpta and More
    May 12, 2021
    Japan’s key reimbursement policy panel on May 12 approved the NHI price listing of 13 new medicines slated for May 19, with Janssen Pharmaceutical’s multiple myeloma (MM) drug carrying the highest peak sales outlook among…

    LATEST

    Ono Nets 5.8% Revenue Growth in FY2020 on Opdivo, Forxiga
    May 12, 2021
    Ono Pharmaceutical on May 11 reported growth of 5.8% in its FY2020 consolidated revenue to reel in 309.2 billion yen on the back of brisk sales of the anti-PD-1 antibody Opdivo (nivolumab) and the SGLT2 inhibitor Forxiga (dapagliflozin).In the year…
    Takeda’s FY2020 Profits Jump on Non-Core Divestitures, Post-Shire Cost Synergies
    May 12, 2021
    Takeda Pharmaceutical enjoyed an 8.5-fold leap in net profit in the year through March 2021 as it yielded gains on a series of non-core asset divestitures and booked lower expenses related to the Shire acquisition…
    Ono Chief Questions Yet Another Re-Pricing for Opdivo, 11.5% Cut in August
    May 12, 2021
    Ono Pharmaceutical President Gyo Sagara on May 11 questioned the health ministry’s plan to apply yet another re-pricing for its flagship PD-1 inhibitor Opdivo (nivolumab) after repeated price cuts over the past years.“It would be…

    FY2021 Drug Maker Employment Survey

    Takeda, Eisai, Chemiphar Ran Early Retirement Programs over Past Year: Survey

    Takeda Pharmaceutical, Eisai, and Nippon Chemiphar offeredearly retirement programs over the past year, a Jiho survey revealed. It appears that not all of them are looking at downsizing, however, with some aggressively seeking to “rejuvenate” their employees by replacing ones…

    COMMENTARY

    Japan’s First CEA-Based Price Tweaks Draw Near, April Listing Round at Earliest
    By Takashi Ohama

    The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…

    INTERVIEW

    From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
    By Yoshinori Sagehashi

    Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

    FY2020 Drug Pricing Reform

    Japan Panel Hammers Out FY2020 Drug Pricing Reform

    Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

    COLUMN

    Pricing Reform in Japan: How Must Life Science Companies Evolve?
    By Eric Persoff

    The past month has seen two significant milestones in healthcare price control measures in Japan: The first “off-year” NHI reimbursement price cuts, and release of the first results under Japan’s “cost-effectiveness assessment” system. Both milestones have been anticipated for quite…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA